Q-omics provides the consensus-scored ZXDA profile across patient tissues and cancer cell-line models. ZXDA expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZXDA is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, ZXDA RNA expression shows 20,289 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where ZXDA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZXDA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZXDA survival associations across molecular data types. ZXDA RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZXDA RNA expression–survival associations across cancer types. High ZXDA expression shows unfavorable associations in UCEC and LUSC, but favorable associations in KIRC, ACC, UCS and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZXDA RNA expression.
This table summarizes ZXDA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZXDA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZXDA shows lower tumor expression in THCA and UCEC and higher tumor expression in KIRC, HNSC, CHOL and KIRP. The THCA box plot shows higher ZXDA RNA expression in normal versus tumor tissue (log2 FC = −0.986, t-test p < 0.001).
This table shows molecular features associated with ZXDA in patient tissues and cancer cell lines. In patient samples, ZXDA shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZXDA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
